J&J says ustekinumab outperformed Amgen drug for psoriasis

09/19/2008 | Wall Street Journal, The · Forbes

Johnson & Johnson unveiled results from a 903-patient study showing that its experimental drug ustekinumab beat Enbrel -- a medicine co-marketed by Amgen and Wyeth -- in treating moderate to severe psoriasis. An Amgen spokeswoman said Enbrel has a "consistent safety profile" and that data from the J&J-funded trial do not prove ustekinumab's long-term safety.

View Full Article in:

Wall Street Journal, The · Forbes

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
ISHN - Chief Compliance Officer
Mountain States Health Alliance
Johnson City, TN
Actuary
Meridian Health Plan
Detroit, MI
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Director, Payer Marketing
Avalere Health
Washington, DC